Atara Biotherapeutics (STU:AT20) Beta: 0.1561 (As of Jun. 25, 2026)


STU:AT20 Atara Biotherapeutics Inc STU:AT20
31 GF Score
Price €8.80
GF Value €1.30
! 7 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Beta?

Atara Biotherapeutics STU:AT20 31 Beta is 0.1561 as of Jun. 25, 2026. GuruFocus rates STU:AT20 with a GF Score™ of 31/100 and a GF Value™ of €1.30. The stock has 7 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Atara Biotherapeutics's Beta is 0.1561.


Atara Biotherapeutics  (STU:AT20) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Atara Biotherapeutics Beta Related Terms


Atara Biotherapeutics Beta Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics Beta Chart

Atara Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.92 1.33 -0.26 0.69 -0.43

Atara Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.74 1.99 -0.43 0.75

STU:AT20 vs RNTX, IBIO, OSTX: Beta Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Beta falls into.


STU:AT20
31GF Score
Atara Biotherapeutics Inc STU:AT20
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.1561 mean?
Atara Biotherapeutics (STU:AT20) has a Beta of 0.1561 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Atara Biotherapeutics and its competitors.
Is Atara Biotherapeutics' Beta too high?
Atara Biotherapeutics' current Beta is 0.1561. Overall, Atara Biotherapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Beta compare to RNTX and IBIO?
Atara Biotherapeutics' Beta of 0.1561 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current Beta is 0.1561. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Atara Biotherapeutics (STU:AT20) has a current Beta of 0.1561. The stock's GF Value™ is €1.30, compared to a current price of €8.80 — trading 576.7% above its estimated fair value. The current Beta is 0.1561. Atara Biotherapeutics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Atara Biotherapeutics (STU:AT20), the current Beta is 0.1561 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (STU:AT20) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of €8.80 is trading 576.7% above its estimated GF Value™ of €1.30.

Key valuation signals for STU:AT20:

  • Beta: 0.1561
  • GF Value™: €1.30 vs. price of €8.80 (576.7% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the STU:AT20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atara Biotherapeutics Business Description

Other Exchanges ATRA:USA0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score

Get the complete analysis for STU:AT20

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.80
Price
€1.30
GF Value